1. patients known to be pregnant or breastfeeding. 2. patients with unstable ischaemic heart disease or acute stroke 3. patients enrolled in other clinical trials of an investigational medicine within the previous 28 day period 4. patients who refuse to have blood samples taken. 5. known hypersensitivity to icatibant 6. patients who at time of consent are likely to require imminent non-invasive/ invasive ventilatory support or patients already established on continuous positive airway pressure (cpap). 7. patients with chronic heart or lung disease whose oxygen levels are reduced, but are unchanged from baseline

1. patients known to be pregnant or breastfeeding. 2. patients with unstable ischaemic heart disease or acute stroke 3. patients enrolled in other clinical trials of an investigational medicine within the previous 28 day period 4. patients who refuse to have blood samples taken. 5. known hypersensitivity to icatibant 6. patients who at time of consent are likely to require imminent non-invasive/ invasive ventilatory support or patients already established on continuous positive airway pressure (cpap). 7. patients with chronic heart or lung disease whose oxygen levels are reduced, but are unchanged from baseline

patients known to be pregnant or breastfeeding. patients with unstable ischaemic heart disease or acute stroke patients enrolled in other clinical trials of an investigational medicine within the previous 28 day period patients who refuse to have blood samples taken. known hypersensitivity to icatibant patients who at time of consent are likely to require imminent non-invasive/ invasive ventilatory support or patients already established on continuous positive airway pressure (cpap). patients with chronic heart or lung disease whose oxygen levels are reduced, but are unchanged from baseline

patients known to be pregnant or breastfeeding. patients with unstable ischaemic heart disease or acute stroke patients enrolled in other clinical trials of an investigational medicine within the previous 28 day period patients who refuse to have blood samples taken. known hypersensitivity to icatibant patients who at time of consent are likely to require imminent non-invasive/ invasive ventilatory support or patients already established on continuous positive airway pressure (cpap). patients with chronic heart or lung disease whose oxygen levels are reduced, but are unchanged from baseline